International Stem Cell Corporation filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 20, 2026, reporting a net income of $21,778 thousand for the third quarter, driven almost entirely by income from discontinued operations.
Key Highlights
- Net income from discontinued operations: The company reported $22,627 thousand in net income from discontinued operations for the three months ended September 30, 2026, according to the filing.
- Net loss from continuing operations: The company recorded a net loss from continuing operations of $849 thousand for the third quarter of 2026.
- Cash position: Cash was $20,033 thousand as of September 30, 2026, compared to $793 thousand at December 31, 2025.
- Stockholders' equity reversal: Total stockholders' equity shifted to $17,606 thousand at September 30, 2026 from a deficit of $(4,060) thousand at December 31, 2025.
- Accumulated deficit reduced: The accumulated deficit decreased to $(89,616) thousand at September 30, 2026 from $(111,103) thousand at December 31, 2025.
- Shares outstanding: As of November 20, 2026, the registrant had 8,163,389 shares of common stock outstanding, including 159,000 shares from options exercised in Q3 2026.
- Product sales: Product sales for the nine months ended September 30, 2026 were $444 thousand, compared to $443 thousand for the same period in 2025.
International Stem Cell Corporation Q3 2026 Financial Results: Discontinued Operations Reshape the Balance Sheet
According to the filing, International Stem Cell Corporation reported total net income of $21,778 thousand for the three months ended September 30, 2026, compared to $57 thousand for the same period in 2025. The company disclosed that this result was largely attributable to $22,627 thousand in net income from discontinued operations in Q3 2026, up from $748 thousand in Q3 2025. For the nine months ended September 30, 2026, net income from discontinued operations totaled $23,952 thousand, against a net loss from continuing operations of $2,465 thousand over the same period.
The company's balance sheet showed a significant shift, the filing disclosed, with total assets rising to $23,419 thousand at September 30, 2026 from $4,819 thousand at December 31, 2025. Cash increased to $20,033 thousand from $793 thousand over the same period. Total liabilities fell to $1,513 thousand from $4,579 thousand, with the filing noting the elimination of a related party note payable that stood at $3,340 thousand at year-end 2025. An escrow receivable of $2,600 thousand appeared on the September 30, 2026 balance sheet, with no comparable amount at December 31, 2025.
From continuing operations, the company reported total operating expenses of $968 thousand for Q3 2026 versus $819 thousand in Q3 2025, with general and administrative expenses accounting for $707 thousand of the Q3 2026 total. Product sales from continuing operations were $147 thousand for the quarter. Net income allocable to common stockholders for the three months ended September 30, 2026 was $11,246 thousand after undistributed earnings of $10,532 thousand were allocated to participating securities. Basic and diluted net income per common share from discontinued operations was $1.51 for the third quarter of 2026, the filing stated. The company is classified as a non-accelerated filer and smaller reporting company, with no securities registered on a national exchange.
What Was Disclosed
International Stem Cell Corporation filed a 10-Q for Q3 2026 showing that income from discontinued operations of $22,627 thousand in the quarter drove a net income of $21,778 thousand, reversed the stockholders' deficit, and lifted cash to $20,033 thousand from $793 thousand at year-end 2025.



Please wait processing your request...